<DOC>
	<DOCNO>NCT02551861</DOCNO>
	<brief_summary>The purpose study determine 8 week Daclatasvir plus Sofosbuvir without Ribavirin safe effective treatment genotype 3 hepatitis C infect patient without advanced fibrosis liver cirrhosis never treat previously .</brief_summary>
	<brief_title>A Randomized , Open-Label Study Daclatasvir Sofosbuvir With Without Ribavirin 8 Weeks Treatment-Na√Øve , Non-cirrhotic Subjects Infected With Chronic Hepatitis C Virus ( HCV ) Genotype 3</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Sofosbuvir</mesh_term>
	<criteria>For information regard BMS clinical trial participation , please visit www.BMSStudyConnect.com Genotype 3 HCV RNA &lt; 2000000 IU/mL Never take HCV medication Absence advance fibrosis cirrhosis Body mass index ( BMI ) 1840 kg/m^2 Infection HCV genotype 3 ( GT3 ) ; Mixed infection genotype Previously take HCV medication Liver Cirrhosis Evidence decompensated liver disease HIV/ hepatitis B virus ( HBV ) coinfection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>